GLP-1 receptor agonists × lipids

TrialESC heart failure2018

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Abhinav Sharma et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 300 people · 2018

Randomised comparison

Probably lowered lipids

−33.1mg/dL−60.7 to −5.60

As reported

difference −33.1 mg/dL, 95% CI −60.7 to −5.60

Randomised comparison

Probably lowered body weight & composition

−2.07percentage points−3.86 to −0.28

As reported

difference −2.07 %, 95% CI −3.86 to −0.28

Two numbers in the abstract

the abstract, start to end

placebo 12.0 mg/dL; treatment difference -33.1 mg/dL; 95% CI -60.7, -5.6; P =

0.0367; percentage treatment difference -2.07%, 95% CI -3.86, -0.28; P =

← favours treatmentfavours comparator →
could be chance
Lipids
−33.1−60.7 to −5.60
Body weight & composition
−2.07−3.86 to −0.28
GLP-1 receptor agonistsBody weight & compositionLipids

GLP-1 receptor agonists × lipidshelps?one trial

unlikelylikely
0.500.25 without it

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

22 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 30120812